New monoclonal antibody inhibits tumor growth in advanced solid tumors in phase I clinical trial

A newly developed antibody targeting a signalling pathway that is frequently active in solid tumors has shown encouraging signs of efficacy in its first trial in humans, researchers reported at the 24th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Dublin, Ireland (6-9 November 2012). A patient with advanced malignant melanoma has shown signs of tumor shrinkage and has been receiving treatment for more than 30 weeks without any serious adverse side-effects. Other patients with advanced non-small cell lung cancer (NSCLC), mesothelioma, renal-cell cancer and biliary tract cancer also have had extended treatments with stable disease. Read more here.